- Home
- GOODO vs GNLX Comparison
GOODO vs GNLX Comparison
Compare GOODO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GOODO
Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Current Price
Current Price
Company Overview
Basic Information| Metric | GOODO | GNLX |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 110.4M |
| IPO Year | 2003 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GOODO | GNLX |
|---|---|---|
| Price | $20.13 | $2.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 5.7K | ★ 280.4K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $161,336,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $112.64 | ★ N/A |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $19.42 | $2.29 |
| 52 Week High | $22.20 | $8.54 |
Technical Indicators
Market Signals| Indicator | GOODO | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 37.99 | 36.86 |
| Support Level | $19.67 | $2.34 |
| Resistance Level | $20.18 | $2.95 |
| Average True Range (ATR) | 0.29 | 0.15 |
| MACD | -0.13 | -0.01 |
| Stochastic Oscillator | 29.27 | 2.63 |
Price Performance
Historical ComparisonAbout GOODO Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.